Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 500 shares, a decrease of 94.0% from the December 15th total of 8,400 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 5.0 days.

Innate Pharma Price Performance

Shares of OTCMKTS IPHYF remained flat at $2.90 during midday trading on Monday. The company's 50-day moving average is $2.08 and its 200-day moving average is $2.14. Innate Pharma has a 12 month low of $1.28 and a 12 month high of $2.90.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.